Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Buy Greggs (GRG) by Ben McPoland in The Motley Fool
- Sell Inspired (INSE) by Steve Moore in ShareProphets
- Neutral Schroders (SDR) by JP Morgan
- Sell Jaywing (JWNG) by Steve Moore in ShareProphets
- Sell Jubilee Metals Group (JLP) by Tom Winnifrith in ShareProphets
- Sell Jubilee Metals Group (JLP) by Steve Moore in ShareProphets
- Sell Tribe Technology (TRYB) by Steve Moore in ShareProphets
- Outperform Hollywood Bowl Group (BOWL) by RBC Capital
- Buy JD Sports Fashion (JD.) by Harvey Jones in The Motley Fool
- Hold Legal & General Group (LGEN) by Harvey Jones in The Motley Fool
- Sell Gelion (GELN) by Steve Moore in ShareProphets
- Buy GSK (GSK) by Harvey Jones in The Motley Fool
- Neutral Synthomer (SYNT) by UBS
- Neutral Carvana Co Class A (0A79) by UBS
- Equal Weight United Utilities Group (UU.) by Barclays
- Overweight Workspace Group (WKP) by Barclays
- Equal Weight Safestore Holdings (SAFE) by Barclays
- Equal Weight Severn Trent (SVT) by Barclays
- Overweight Pennon Group (PNN) by Barclays
- Overweight Land Securities Group (LAND) by Barclays
Theracryf (TCF) Share Price
NOTE: This is based on 0 open tips for Theracryf (TCF)
| Latest Bid : 0.50p | Latest Ask : 0.55p |
| High Today : 0.54p | Low Today : 0.51p |
| This Years High : 1.85p | This Years Low : 0.51p |
| Volume : 9,346 | MKT Cap : £2.23M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Theracryf (TCF) Overview
TheraCryf is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf's strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. The Company's clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos' neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.Theracryf (TCF) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 0.50p | Latest Ask : 0.55p |
| High Today : 0.54p | Low Today : 0.51p |
| This Years High : 1.85p | This Years Low : 0.51p |
| Volume : 9,346 | MKT Cap : £2.23M |
Theracryf Overview
TheraCryf is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf's strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. The Company's clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos' neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.